Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6425
    -0.0000 (-0.00%)
     

  • OIL

    82.87
    +0.14 (+0.17%)
     

  • GOLD

    2,406.00
    +8.00 (+0.33%)
     

  • Bitcoin AUD

    100,621.84
    +1,549.65 (+1.56%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.66%)
     

  • AUD/EUR

    0.6026
    -0.0005 (-0.08%)
     

  • AUD/NZD

    1.0896
    +0.0021 (+0.20%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,186.01
    -208.30 (-1.20%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,954.94
    +179.56 (+0.48%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Compared to Estimates, Danaher (DHR) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

Danaher (DHR) reported $7.17 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 6.8%. EPS of $2.36 for the same period compares to $2.76 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $7.03 billion, representing a surprise of +1.97%. The company delivered an EPS surprise of +4.42%, with the consensus EPS estimate being $2.26.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total Growth - Organic sales (Core): 6% versus -3.1% estimated by four analysts on average.

  • Total sales- Diagnostics: $2.38 billion versus the four-analyst average estimate of $2.26 billion. The reported number represents a year-over-year change of -10.1%.

  • Total sales- Life Sciences: $1.71 billion compared to the $1.70 billion average estimate based on four analysts. The reported number represents a change of -56% year over year.

  • Total sales- Environmental & Applied Solutions: $1.22 billion versus the four-analyst average estimate of $1.42 billion. The reported number represents a year-over-year change of +4.8%.

View all Key Company Metrics for Danaher here>>>

Shares of Danaher have returned +2.6% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Danaher Corporation (DHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research